All In Biotech

Drug Trial Radar · NCT00315341

Starting Treatment With Agonist Replacement Therapies (START)

Last checked: Nov 19, 2026Latest source record: Jan 6, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 1,269 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,269

Actual

Start

Apr 2006

Primary completion

Aug 2010

Study completion Aug 2010

Sponsor

Lead sponsor
University of California, Los AngelesAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute on Drug Abuse (NIDA)
First posted
Apr 18, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The Food and Drug Administration (FDA) has requested a study comparing buprenorphine/naloxone (BUP/NX) and methadone (MET) on indices of hepatic safety.

Conditions

  • Opiate-related Disorders

Interventions

  • Buprenorphine/naloxoneDrug

    Participants receive up to 16 mg BUP/4 mg NX on day 1 and up to 32 mg BUP/8 mg NX on day 2. It is recommended that dose changes be made in 2 to 8 mg increments, with the range of allowable daily doses between 2 mg and 32 mg starting on day 3 and thereafter according to clinical impression and depending upon the participant's clinical need.

  • MethadoneDrug

    Participants will receive a maximum of 30 mg for the first dose and a maximum of 40 mg on Day 1. It is recommended that participants receive a dose on day 2 that is 10 mg higher than their total day 1 dose, and a dose on day 3 that is 10 mg higher than their total day 2 dose, unless, in the clinical judgment of the physician, a slower induction is needed. Doses will be adjusted on Day 4 and thereafter according to clinical impression and depending upon the participant's clinical need with no specific upper limit.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Hepatic SafetyTime frame: 24 Weeks

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Matrix Institute

    Los Angeles, California

  • Bi-Valley Medical Clinic INC.

    Sacramento, California

  • BAART; Turk Street Clinic

    San Francisco, California

  • Hartford Dispensary

    Hartford, Connecticut

  • CT Counseling Centers

    Waterbury, Connecticut

  • Addiction Research & Treatment Corp

    Brooklyn, New York

  • CODA-Research

    Portland, Oregon

  • NET Steps

    Philadelphia, Pennsylvania

  • Evergreen Treatment Services

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.